
Opinion|Videos|January 6, 2026
PROs From ASCENT-04 Study of Sacituzumab Govitecan Plus Pembrolizumab in First-Line TNBC
Author(s)Laura Huppert, MD
Advertisement
Episodes in this series
Laura Huppert, MD, highlights patient-reported outcomes from the phase 3 ASCENT-04 trial which compared first-line treatment with the antibody-drug conjugate sacituzumab govitecan plus the PD-1 inhibitor pembrolizumab vs pembrolizumab plus chemotherapy in patients with PD-L1–positive advanced triple-negative breast cancer. Huppert discusses specific PROs and their impact on quality of life, along with the overall significance of PRO data in fully understanding patients’ experience with specific treatments.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5



















